The Insider and EVP GMDA – CMO of Vertex Pharmaceuticals (VRTX), Jeffrey Chodakewitz, Sold 5,122 Shares; Realnetworks (RNWK) Shorts Raised By 5.73%

February 15, 2018 - By Martha Paddon

5,122 shares of Vertex Pharmaceuticals Inc Ma were sold by Jeffrey Chodakewitz, the company’s EVP GMDA – CMO. The mentioned shares are valued at about $772,493 which has been calculated on the basis of the average transactions stock price ($150.8 for a share). This is not his first insider trade, in the last month, he unloaded another 9,009 shares worth $1,467,127 USD. For more info of this sale please read the (SEC)’s Form 4 freely available here. This is a stocks unloading that is not going to stay ignored as Jeffrey already has in hand 69,663 shares accounting for 0.03% of the Company’s market cap

Realnetworks Incorporated (NASDAQ:RNWK) had an increase of 5.73% in short interest. RNWK’s SI was 1.17M shares in February as released by FINRA. Its up 5.73% from 1.10M shares previously. With 60,800 avg volume, 19 days are for Realnetworks Incorporated (NASDAQ:RNWK)’s short sellers to cover RNWK’s short positions. The SI to Realnetworks Incorporated’s float is 5.89%. The stock decreased 1.69% or $0.05 during the last trading session, reaching $2.9. About 63,209 shares traded. RealNetworks, Inc. (NASDAQ:RNWK) has risen 3.19% since February 15, 2017 and is uptrending. It has underperformed by 13.51% the S&P500.

The stock increased 2.02% or $3.12 during the last trading session, reaching $157.26. About 1.99M shares traded or 13.96% up from the average. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since February 15, 2017 and is uptrending. It has outperformed by 28.99% the S&P500.

Investors sentiment increased to 1.62 in Q3 2017. Its up 0.11, from 1.51 in 2017Q2. It increased, as 32 investors sold Vertex Pharmaceuticals Incorporated shares while 151 reduced holdings. 79 funds opened positions while 217 raised stakes. 231.42 million shares or 0.04% more from 231.33 million shares in 2017Q2 were reported. Laurion Capital Lp stated it has 5,700 shares or 0% of all its holdings. Cim Mangement holds 0.19% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 3,526 shares. 647,503 were reported by Eaton Vance Management. State Treasurer State Of Michigan holds 0.09% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 76,468 shares. First Light Asset Limited reported 1.13% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). 1,506 were reported by Quantbot L P. Brinker Capital owns 9,819 shares for 0.06% of their portfolio. Jacobs Levy Equity Mgmt holds 0.55% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 184,950 shares. Bnp Paribas Arbitrage stated it has 0.04% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Sphera Funds Limited invested in 0.45% or 20,823 shares. 34,200 are owned by Art Ltd Liability Co. Parkwood Limited Com, Ohio-based fund reported 1,324 shares. Fifth Third Financial Bank owns 397 shares or 0% of their US portfolio. Cap Fund Mngmt Sa accumulated 162,166 shares. C Ww Wide Grp A S owns 38,146 shares.

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals has $212.0 highest and $85.0 lowest target. $178.31’s average target is 13.39% above currents $157.26 stock price. Vertex Pharmaceuticals had 96 analyst reports since July 31, 2015 according to SRatingsIntel. RBC Capital Markets maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Thursday, April 28. RBC Capital Markets has “Outperform” rating and $115 target. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, September 15. Guggenheim maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Wednesday, January 31. Guggenheim has “Buy” rating and $190.0 target. The rating was maintained by Credit Suisse on Tuesday, February 13 with “Outperform”. The firm has “Buy” rating given on Friday, June 23 by Needham. JMP Securities maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Tuesday, February 13. JMP Securities has “Market Outperform” rating and $211 target. Stifel Nicolaus maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Thursday, January 26. Stifel Nicolaus has “Buy” rating and $100 target. On Wednesday, July 19 the stock rating was upgraded by Cowen & Co to “Outperform”. The stock has “Buy” rating by BMO Capital Markets on Monday, September 25. Stifel Nicolaus initiated Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Tuesday, December 1. Stifel Nicolaus has “Buy” rating and $160 target.

Since August 31, 2017, it had 0 insider buys, and 37 sales for $109.10 million activity. Arbuckle Stuart A sold $365,270 worth of stock. ALTSHULER DAVID sold $8.83M worth of stock. SMITH IAN F sold $334,232 worth of stock or 2,125 shares. The insider Parini Michael sold $600,680. On Monday, October 2 Chodakewitz Jeffrey sold $521,198 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 3,437 shares. The insider Sachdev Amit sold $5.80M. LEIDEN JEFFREY M had sold 99,563 shares worth $15.63M on Tuesday, January 16.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $39.83 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 151.21 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Investors sentiment increased to 1.2 in 2017 Q3. Its up 0.15, from 1.05 in 2017Q2. It improved, as 2 investors sold RealNetworks, Inc. shares while 18 reduced holdings. 6 funds opened positions while 18 raised stakes. 19.34 million shares or 1.26% more from 19.10 million shares in 2017Q2 were reported. Jpmorgan Chase & Company holds 1,713 shares or 0% of its portfolio. Park West Asset Mngmt Ltd Liability holds 0.5% of its portfolio in RealNetworks, Inc. (NASDAQ:RNWK) for 1.74 million shares. 27,825 were reported by Pub Employees Retirement Association Of Colorado. Moreover, Ameritas Investment has 0% invested in RealNetworks, Inc. (NASDAQ:RNWK) for 1,733 shares. State Street has 0% invested in RealNetworks, Inc. (NASDAQ:RNWK) for 470,160 shares. Blackrock Inc holds 1.92 million shares or 0% of its portfolio. California State Teachers Retirement System has invested 0% of its portfolio in RealNetworks, Inc. (NASDAQ:RNWK). Morgan Stanley invested in 30,369 shares. Sei Invs Communication holds 0% of its portfolio in RealNetworks, Inc. (NASDAQ:RNWK) for 4 shares. Schwab Charles Investment Mngmt Inc invested in 0% or 53,175 shares. The New York-based Ny State Common Retirement Fund has invested 0% in RealNetworks, Inc. (NASDAQ:RNWK). Northern Tru has 288,065 shares. 2.44 million are held by Dimensional Fund Advsrs L P. Legal General Group Public Limited Company holds 0% or 3,691 shares in its portfolio. Wells Fargo Company Mn stated it has 0% of its portfolio in RealNetworks, Inc. (NASDAQ:RNWK).